The estimated Net Worth of Mark Germain is at least $1.03 Million dollars as of 15 March 2018. Mr. Germain owns over 45,873 units of Pluri Inc stock worth over $513,944 and over the last 17 years he sold PSTI stock worth over $511,239. In addition, he makes $0 as Independent Director at Pluri Inc.
Mark has made over 4 trades of the Pluri Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 45,873 units of PSTI stock worth $67,892 on 15 March 2018.
The largest trade he's ever made was selling 67,858 units of Pluri Inc stock on 4 March 2014 worth over $272,789. On average, Mark trades about 7,859 units every 64 days since 2007. As of 15 March 2018 he still owns at least 513,944 units of Pluri Inc stock.
You can see the complete history of Mr. Germain stock trades at the bottom of the page.
Mark S. Germain serves as Independent Director of the Company. Mr. Germain has been a merchant banker serving primarily the biotech and life sciences industries for over five years. He has been involved as a founder, director, chairman of the board of, and/or investor in, over twenty companies in the biotech field and assisted many of them in arranging corporate partnerships, acquiring technology, entering into mergers and acquisitions, and executing financings and going public transactions. He graduated from New York University School of Law in 1975, Order of the Coif, and was a partner in a New York law firm practicing corporate and securities law before leaving in 1986. Since then, and until he entered the biotech field in 1991, he served in senior executive capacities, including as president of a public company that was sold in 1991. In addition to being a director of the Company, Mr. Germain is a Managing Director at The ÆNTIB Group, a boutique merchant bank. From June 2018 through September 30, 2019, Mr. Germain also served as Vice Chairman of the board of BiondVax Pharmaceuticals Ltd., a company based in Israel engaging in a Phase III clinical trials for a universal flu vaccine, and, effective September 30, 2019 has served as the chairman of the board of BiondVax Pharmaceuticals Ltd.
Mark Germain is 69, he's been the Independent Director of Pluri Inc since 2014. There are no older and 7 younger executives at Pluri Inc.
Mark's mailing address filed with the SEC is MATAM PARK, BUILDING #5, , HAIFA, L3, 3508409.
Over the last 17 years, insiders at Pluri Inc have traded over $7,081,854 worth of Pluri Inc stock and bought 2,345,914 units worth $14,327,834 . The most active insiders traders include Wolf Capital Limited Part..., Zami Aberman, and Israel Ben Yoram. On average, Pluri Inc executives and independent directors trade stock every 64 days with the average trade being worth of $54,123. The most recent stock trade was executed by Zami Aberman on 10 February 2022, trading 80,616 units of PSTI stock currently worth $145,109.
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a
Pluri Inc executives and other stock owners filed with the SEC include: